BioAge Labs, Inc. BIOA

EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • ROTH Healthcare Opportunities Conference (New York, September 29, 2026): BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, A

Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline results expected in the second half of 2027 Beyond DME, results will inform development strategy in other NLRP3-driven retinal diseases, including geographic atrophy EMERYVILLE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge” or the “Company”),

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 20,200 stock options of series 2019/2028.

First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 QUELL-DME, Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema, planned to initiate in mid-2026, with data anticipated in mid-2027; results expected to support development across inflammation-driven retinal diseases Hosted R&D Day focused on NLRP3 inhibition, featuring Phase 1 d

BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients with early Alzheimer's disease (AD) enrolled in the study remained stable (75.9%) or improved (6.6%) while receiving Leqembi over an average of 17 months. The results were consistent across sex, race, ethnicity and APOE genotype.

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best low-priced pharma stocks on this list. TheFly reported on June 16 that BIOA announced the dosing of the first participant in QUELL-CV, a Phase 2 proof-of-concept study evaluating BGE-102. The investigational therapy […]

BioAge Labs has dosed the first participant in QUELL-CV, a 12-week, 160-patient Phase 2 proof-of-concept trial of its oral NLRP3 inhibitor BGE-102 in adults with obesity, elevated inflammation, and additional cardiovascular risk factors. An interesting angle is that BGE-102 emerged from BioAge’s human aging data platform, linking lower NLRP3 activity with greater longevity and positioning the drug at the intersection of cardiovascular and aging biology. We’ll now examine how this Phase 2...

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3 Trial builds on previously reported Phase 1 results in which BGE-102 achieved potential best-in-class hsCRP reductions and was well tolerated acro

We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best small cap pharma stocks to buy right now. TheFly reported on May 13 that BIOA received newly initiated coverage with a Buy rating and a $40 price target by […]

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keefe, Bruyette & Woods analyst Alex Bond initiated coverage on Coinshares PLC (NASDAQ:CSHR) with an Outperform rating and announces Price Target of $9. CoinShares shares closed at $6.11 on Tuesday. See how other analysts view this stock. BTIG analyst Thomas Shrader initiated coverage on BIOAGE L

BioAge Labs, Inc. ( NASDAQ:BIOA ) investors will be delighted, with the company turning in some strong numbers with its...